Security Snapshot

UNITED THERAPEUTICS Corp - Common Stock (UTHR) Institutional Ownership

CUSIP: 91307C102

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

825

Shares (Excl. Options)

41,578,250

Price

$487.25

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
UTHR on Nasdaq
Shares outstanding
42,833,193
Price per share
$592.98
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
41,578,250
Total reported value
$20,237,803,944
% of total 13F portfolios
0.02%
Share change
+754,770
Value change
+$453,058,249
Number of holders
825
Price from insider filings
$592.98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • UTHR - UNITED THERAPEUTICS Corp - Common Stock is tracked under CUSIP 91307C102.
  • 825 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 825 to 135 between Q4 2025 and Q1 2026.
  • Reported value moved from $20,237,803,944 to $573,020,174.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 825 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 91307C102?
CUSIP 91307C102 identifies UTHR - UNITED THERAPEUTICS Corp - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of UNITED THERAPEUTICS Corp - Common Stock (UTHR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 5.7% +24% $1,189,616,977 +$202,245,781 2,441,492 +20% Wellington Management Group LLP 31 Dec 2025
STATE STREET CORP 4.9% $661,670,195 2,199,994 STATE STREET CORPORATION 31 Dec 2024

As of 31 Dec 2025, 825 institutional investors reported holding 41,578,250 shares of UNITED THERAPEUTICS Corp - Common Stock (UTHR). This represents 97% of the company’s total 42,833,193 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of UNITED THERAPEUTICS Corp - Common Stock (UTHR) together control 66% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 5,170,766 -3.4% 0.04% $2,519,455,839
VANGUARD GROUP INC 9.7% 4,176,016 -5.5% 0.03% $2,034,763,797
Avoro Capital Advisors LLC 6.1% 2,606,060 +29% 12% $1,269,802,735
WELLINGTON MANAGEMENT GROUP LLP 5.7% 2,441,492 +75% 0.21% $1,189,616,979
RENAISSANCE TECHNOLOGIES LLC 4.5% 1,909,259 -12% 1.4% $930,286,448
STATE STREET CORP 4.3% 1,842,411 -4.2% 0.03% $897,714,760
AQR CAPITAL MANAGEMENT LLC 3% 1,281,699 +30% 0.33% $624,507,810
GEODE CAPITAL MANAGEMENT, LLC 2.8% 1,193,064 -4.5% 0.04% $580,238,360
JANUS HENDERSON GROUP PLC 1.9% 796,101 +75% 0.17% $387,801,106
ASSETMARK, INC 1.5% 634,956 -1.7% 0.63% $309,382,109
Invesco Ltd. 1.4% 608,759 -4.5% 0.05% $296,617,825
NORGES BANK 1.4% 602,191 0.03% $293,417,565
DIMENSIONAL FUND ADVISORS LP 1.2% 528,210 +3% 0.05% $257,405,220
DEERFIELD MANAGEMENT COMPANY, L.P. 0.99% 425,993 0% 2.7% $207,565,089
NORTHERN TRUST CORP 0.98% 418,427 -6.4% 0.03% $203,878,557
LSV ASSET MANAGEMENT 0.95% 408,065 -41% 0.43% $198,830,000
FMR LLC 0.94% 403,830 +61% 0.01% $196,766,016
MORGAN STANLEY 0.91% 389,275 -11% 0.01% $189,675,140
PRICE T ROWE ASSOCIATES INC /MD/ 0.82% 352,086 +17% 0.02% $171,555,000
Bank of New York Mellon Corp 0.78% 333,629 -5.1% 0.03% $162,560,825
Swedbank AB 0.76% 324,772 -1.3% 0.15% $158,245,158
BAILLIE GIFFORD & CO 0.75% 323,016 0.13% $157,389,546
D. E. Shaw & Co., Inc. 0.72% 306,971 +374% 0.11% $149,571,620
Pictet Asset Management Holding SA 0.72% 306,837 -4.6% 0.15% $149,668,916
Caisse de depot et placement du Quebec 0.69% 296,320 +202% 0.24% $144,381,920

Institutional Holders of UNITED THERAPEUTICS Corp - Common Stock (UTHR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 973,378 $573,020,174 +$32,916,082 $592.98 135
2025 Q4 41,578,250 $20,237,803,944 +$453,058,249 $487.25 825
2025 Q3 40,884,780 $17,141,521,441 -$1,065,484,238 $419.21 701
2025 Q2 43,924,518 $12,621,620,981 -$132,393,705 $287.35 662
2025 Q1 44,441,020 $13,691,236,526 +$58,445,640 $308.27 661
2024 Q4 43,992,356 $15,526,430,783 +$60,965,879 $352.84 667
2024 Q3 43,520,361 $15,594,079,368 -$719,584,018 $358.35 617
2024 Q2 45,751,455 $14,568,456,882 +$331,436,428 $318.55 557
2024 Q1 45,081,525 $10,361,695,587 +$141,369,039 $229.72 518
2023 Q4 44,516,671 $9,786,687,446 +$24,490,915 $219.89 528
2023 Q3 44,424,001 $10,034,347,626 -$137,617,629 $225.87 503
2023 Q2 44,929,853 $9,916,555,660 -$53,987,464 $220.75 466
2023 Q1 45,106,269 $10,099,164,591 -$14,220,192 $223.96 499
2022 Q4 44,906,712 $12,485,251,712 +$52,130,518 $278.09 506
2022 Q3 44,754,285 $9,370,900,072 +$62,537,202 $209.38 450
2022 Q2 44,045,171 $10,378,944,055 +$127,464,630 $235.64 462
2022 Q1 44,003,492 $7,893,754,591 +$134,402,123 $179.41 416
2021 Q4 43,119,761 $9,315,950,531 -$262,053,365 $216.08 409
2021 Q3 44,131,602 $8,148,234,087 +$112,030,536 $184.58 415
2021 Q2 43,453,740 $7,794,694,945 +$9,014,738 $179.41 397
2021 Q1 43,411,843 $7,268,500,823 +$26,763,473 $167.27 384
2020 Q4 43,003,015 $6,528,125,218 +$196,460,628 $151.79 347
2020 Q3 41,894,495 $4,231,829,902 -$29,144,918 $101.00 320
2020 Q2 42,050,372 $5,086,767,081 -$63,243,154 $121.00 338
2020 Q1 42,930,204 $4,071,608,811 +$175,279,566 $94.83 293
2019 Q4 41,222,454 $3,630,167,945 -$10,769,148 $88.08 313
2019 Q3 41,360,375 $3,298,822,179 -$43,165,509 $79.75 293
2019 Q2 41,925,901 $3,270,999,774 -$120,924,183 $78.06 310
2019 Q1 42,851,966 $5,019,717,224 -$2,500,101 $117.37 365
2018 Q4 42,797,039 $4,647,344,925 -$44,377,540 $108.90 349
2018 Q3 42,931,668 $5,477,659,096 +$109,487,455 $127.88 358
2018 Q2 42,156,011 $4,759,186,005 -$156,681,448 $113.15 363
2018 Q1 43,460,877 $4,868,793,558 -$69,339 $112.36 365
2017 Q4 43,844,012 $6,467,580,193 +$1,702,122 $147.95 396
2017 Q3 43,668,487 $5,125,733,185 -$334,513,080 $117.19 366
2017 Q2 46,301,037 $6,009,612,999 -$200,410,807 $129.73 370
2017 Q1 47,751,240 $6,465,099,833 +$610,508,007 $135.38 403
2016 Q4 47,458,415 $6,801,787,668 -$130,023,048 $143.43 399
2016 Q3 48,612,849 $5,737,572,105 -$95,788,438 $118.08 386
2016 Q2 49,467,005 $5,240,809,009 -$126,453,122 $105.92 376
2016 Q1 50,901,388 $5,672,819,733 -$72,469,397 $111.43 392
2015 Q4 51,032,866 $7,993,767,829 +$6,715,778 $156.61 379
2015 Q3 50,877,238 $6,677,428,627 -$88,605,466 $131.24 364
2015 Q2 51,009,203 $8,872,097,786 -$239,100,161 $173.95 382
2015 Q1 52,380,211 $9,025,014,777 +$258,920,695 $172.43 364
2014 Q4 51,016,976 $6,610,861,799 -$258,272,236 $129.49 329
2014 Q3 52,842,225 $6,798,751,692 +$110,623,362 $128.65 316
2014 Q2 52,197,884 $4,620,244,446 -$147,923,232 $88.49 302
2014 Q1 53,760,278 $5,055,784,054 -$116,189,342 $94.03 305